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Abstract
Background: Non-alcoholic steatohepatitis (NASH) is often seen together with components of metabolic
syndrome. The aim of this study was to assess the risk of de novo post-transplant type 2 diabetes (DM) in liver
transplant recipients with NASH.
Methods: All adult patients from the Scientific Registry of Transplant Recipients (2003–2012) transplanted for
NASH or cryptogenic cirrhosis (the NASH cohort) without pre-transplant DM were included in this retrospective
cross-sectional study.
Results: Total 2,916 NASH subjects and 14,268 controls with non-HCV related cirrhosis or hepatocellular carcinoma
were included. Patients with NASH were, on average, 6 years older, more likely female and overweight/obese.
By 5 years post-transplant, 39.8 % NASH vs. 27.0 % controls developed at least one onset of de novo DM; this was
observed starting 6 months post-transplant: 22.9 % vs. 16.7 % (relative risk 1.38). Later in follow-up, the relative
risk of de novo DM was also higher in NASH: 1.46 by 3 years, 1.47 by 5 years (all p < 0.0001). After exclusion of
DM that resolved after the first year, long-term DM remained higher in the NASH cohort: 7.6 % vs. 4.3 %, p < 0.0001. In
multivariate analysis, after adjustment for confounders including the use of immunosuppressants, having NASH was
independently associated with development of de novo post-transplant DM: adjusted hazard ratio (95 % CI) = 1.29
(1.18–1.42), p < 0.0001.
Conclusions: Liver transplant recipients with NASH have a higher risk of de novo post-transplant DM. This suggests
the presence of an underlying metabolic disorder beyond fatty liver that may be causative for both NASH and type 2
diabetes.
Keywords: Liver transplantation, Type 2 diabetes, NASH
Background
The prevalence of non-alcoholic fatty liver disease
(NAFLD) is increasing along with the worldwide
epidemics of obesity and related conditions such as type
2 diabetes (DM) and metabolic syndrome [1–5].
Although NAFLD describes a broad spectrum ranging
from simple hepatic steatosis to non-alcoholic steatohe-
patitis (NASH), it is only those with NASH that are
most likely to progress to cirrhosis, hepatocellular car-
cinoma and, ultimately, liver failure [1–3]. The overall
rate of progression to end-stage liver disease is esti-
mated to be as low as 2-3 % of non-cirrhotic NAFLD
patients and up to 13 % in cirrhotic NASH [4, 5].
However, given the size of affected population - the
prevalence of NAFLD in the U.S. is estimated to be
in the range of 30–50 % [6, 7], − the incidence of
end-stage liver disease due to NASH can still be
substantial and, more importantly, increasing. Indeed,
U.S. transplant centers have recently reported a
rapidly growing number of patients who are now re-
ceiving liver transplant because of the etiology of
their liver disease being NASH [8, 9].
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It is estimated that up to 90 % of NAFLD patients may
exhibit at least one component of metabolic syndrome
such as obesity, insulin resistance or type 2 diabetes,
hyperlipidemia, and cardiovascular disease [4, 10]. In
fact, the overlap of NAFLD and metabolic syndrome is
so extensive that NAFLD is sometimes referred to as
hepatic manifestation of metabolic syndrome [11].
Although metabolic syndrome components such as type
2 diabetes are known to be risk factors for progression
of NAFLD to more advanced forms [12, 13], the causal
relationship between the two is likely complex and also
involves other factors such as increased visceral adipose
tissue mass and excessive inflammatory signaling. The
precise pathophysiologic mechanisms that link NAFLD
and type 2 diabetes are not completely clear, but are
currently believed to include altered proinflammatory
adipo-cytokine production, increased free fatty acid re-
lease and the resulting oxidative stress [4, 7]. Further-
more, a number of genetic factors that could potentially
drive both insulin resistance and NAFLD progression
have already been reported [7, 14–17].
After successful liver transplantation, the underlying
metabolic disorder that initially caused progression to
NASH and to end-stage liver disease may not resolve
and, thus, may still promote both recurrent NASH and
metabolic syndrome components in transplanted pa-
tients [6, 18, 19]. Indeed, high rate of NASH recurrence
in such patients has already been reported: as many as
40 % to 60 % of NASH patients developed graft steatosis
as early as 1 year post-transplant [6, 18, 19]. On the
other hand, the rate of post-transplant DM in solid
organ transplant recipients is high regardless of etiology
of their end-stage organ failure, solely due to immuno-
suppression with diabetogenic agents such as corticoste-
roids and tacrolimus [20, 21]. Given that, it is unclear
whether the risk of post-transplant DM in liver trans-
plant recipients with NASH is additionally affected.
However, we suggest that the pathophysiologic mechan-
ism responsible for the initial development and further
recurrence of NASH, genetic or environmental, may also
contribute to an increased risk of developing DM after
receiving liver transplant.
The aim of this study was to compare the rates of
developing de novo post-transplant DM in patients
transplanted for NASH and in those transplanted for
other causes of end-stage liver disease.
Methods
In this study, we used data from the Scientific Registry
of Transplant Recipients (SRTR) released on June 1,
2013. The SRTR data system includes data on all donor,
wait-listed candidates, and transplant recipients in the
US, submitted by the members of the Organ Procurement
and Transplantation Network (OPTN), and has been
described elsewhere. The Health Resources and Services
Administration (HRSA), U.S. Department of Health and
Human Services provides oversight to the activities of the
OPTN and SRTR contractors.
Included were liver transplant recipients of 18+ years
of age at the moment of transplant who were discharged
alive after receiving a heterotopic or an orthotopic liver
transplant from a deceased or a living donor. Patients
with pre-transplant history of type 2 diabetes were
excluded; thus, only de novo episodes of DM were
studied. We also excluded patients of less than 18 years
of age at the time of transplant, patients receiving liver
re-transplants, and patients who died before discharge.
Liver transplant recipients with NASH listed as an in-
dication for liver transplant with or without liver malig-
nancy were included in the target cohort. Since in the
United States cryptogenic cirrhosis is largely presumed
to be burned out NASH [22–29], we also considered all
subjects with an indication for liver transplantation be-
ing cryptogenic cirrhosis to have had NASH. Addition-
ally, since hepatitis C virus (HCV) is known to have a
diabetogenic effect of its own [30, 31], we also excluded
all subjects with HCV-related indication for transplant-
ation or positive HCV serology. Finally, the control non-
NASH cohort included subjects with all other causes of
chronic liver disease, including alcoholic cirrhosis, hepa-
titis B, biliary cirrhosis, and metabolic disorders.
Post-transplant type 2 diabetes
The primary outcome used in this study was time to
development of de novo post-transplant DM in liver
transplant recipients who did not have DM before trans-
plantation and who were discharged alive after receiving
the transplant. Post-transplant follow-up records submit-
ted to the SRTR by UNOS were used to assess post-
transplant diabetes status. Since regular reporting of
diabetes status in post-transplant follow-up did not start
until 2003, only patients transplanted between 2003 and
2012 were included in this study. Patients were
followed-up 6 months after transplantation and then an-
nually until death, graft failure, or loss to follow-up.
Reporting of diabetes status in liver transplant recipients
by UNOS was largely discontinued after 5 years post-
transplant, so post-transplant DM was assessed up to
5 years only.
In patients with at least two follow-up records, reso-
lution of post-transplant DM was presumed in those
who had a recorded onset of DM followed by a recorded
absence of DM in a later follow-up. On the other hand,
long-term DM was defined as DM reported in at least
two consecutive yearly follow-ups. Time from the trans-
plant to the first onset of DM and from the first onset to
its resolution was calculated in years; the follow-up
yearly codes were used.
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Study definitions
As reported in the SRTR data collection, transplant re-
cipients' age, gender, ethnicity, citizenship, education,
employment status, and the primary payer (public insur-
ance included Medicare, Medicaid, VA, or another
government-sponsored plan) were recorded. Functional
status at the moment of transplant was reported on a
10–100 scale; the highest value of 100 indicates the best
possible health with no evidence of any disease, and the
lowest value of 10 indicates moribund status with fatal
processes progressing rapidly. Being obese at the time of
transplant was defined as having BMI of at least 30.0;
overweight was defined as BMI between 25.0 and 30.0.
Pre-transplant history of hypertension, peripheral vascu-
lar disease, coronary artery disease (CAD), stroke, cancer
(solid organ or lymphoproliferative), pulmonary embol-
ism, chronic obstructive pulmonary disease was also
recorded.
In addition to having NASH, the transplant diagnosis
of primary liver malignancy was defined as having
hepatocellular carcinoma, fibrolamellar hepatocellular car-
cinoma, cholangiocarcinoma, hepatoblastoma, heman-
gioendothelioma, hemangiosarcoma, angiosarcoma, and
other types of primary liver malignancy.
The MELD score for the study cohort was calculated
using labs collected before transplantation or, if unavail-
able, the last record of the wait-listed candidate was
used. Furthermore, post-transplant length of inpatient
stay was calculated from the date of transplant to the
date of discharge; the total length of stay was calculated
from the date of admission to the date of discharge.
The use of immunosuppressive medications including
mycophenolate (mycophenolate mofetil or mycopheno-
late sodium, branded or generic), tacrolimus (branded
original, modified release, or generic), and steroids
(prednisone, methylprednisolone, branded or generic)
was recorded at the moment of transplant and at every
follow-up.
Statistical analysis
Clinico-demographic parameters of NASH patients were
compared to those of the controls using chi-square test
for homogeneity and Wilcoxon non-parametric test.
Predictors of time to development of de novo post-
transplant DM were evaluated using a multivariate Cox
proportional hazard model; the time to development of
DM was calculated from the transplant to the first
recorded DM onset, and censoring time was the last re-
corded absence of DM. In order to account for the effect
of immunosuppressive drugs on development of post-
transplant DM, the use of immunosuppressants was
recorded at or before the first onset of DM; if the first
use of a particular immunosuppressant happened later
than the first onset of DM, such use was not recorded.
Two-sided p-values of 0.05 or less were considered
statistically significant after Bonferroni multiple test
correction.
All statistical analyses were run in SAS 9.3 (SAS
Institute, Cary, NC).
Ethics statement
The study was granted approval by Inova Institutional
Review Board.
Results
In 2003–2012, 5079 adult patients with NASH with at
least one follow-up record were transplanted for the first
time and discharged from 114 different transplant cen-
ters across the U.S. (both transplant centers and patients
were de-identified in the SRTR database). Of those, 2916
were reported to have no type 2 diabetes before trans-
plantation, and were used in this study. Similarly, of
non-NASH non-HCV controls, 17,447 adult patients re-
ceiving their first liver transplant were initially selected,
and then 14,268 without pre-transplant history of type 2
DM were included in this study.
The number of NASH transplants without pre-
transplant DM per year ranged from 169 in 2003 to 374
in 2011. In the NASH cohort, 1,723 (59.1 %) were in fact
transplanted for cryptogenic cirrhosis. Of non-NASH
controls, 29.6 % had alcoholic liver disease, 6.6 % had
chronic hepatitis B, 6.5 % had metabolic disease such
as α1-antitrypsin deficiency, Wilson’s disease or
hemochromatosis, 9.7 % had biliary cirrhosis (primary
or secondary), 12.7 % had primary sclerosing cholangitis,
6.1 % had autoimmune hepatitis, and 15.4 % had primary
liver malignancy of unspecified etiology. Of all patients
included in this study, 62.3 % were followed-up for at
least 3 years, and 39.6 % for 5 years.
The demographics of NASH transplant recipients and
controls is summarized in Table 1. Patients with NASH
were, on average, 6.0 years older, significantly more likely
Caucasian (81.6 % vs. 72.8 %), less likely male (56.1 % vs.
60.1 %), African-American (4.0 % vs. 9.0 %) or Asian
(1.7 % vs. 6.9 %), more frequently covered by a publicly
sponsored health insurance plan (Medicare, Medicaid,
etc.: 39.2 % vs. 33.4 %), and less likely employed at the
time of transplant (13.3 % vs. 17.7 %) (all p < 0.0001).
The functional status that reflected the severity of dis-
ability at the moment of transplant was similar between
NASH patients and controls (p > 0.05) (Table 1).
Clinical presentation of NASH transplant recipients as
opposed to controls is summarized in Table 2. Patients
with NASH were expectedly more overweight or obese
(77.5 % vs. 57.6 %). Despite not having pre-transplant
DM, they also had higher prevalence of metabolic
syndrome components and related conditions including
drug-treated hypertension (23.4 % vs. 17.2 %) and
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coronary artery disease (3.1 % vs. 1.5 %) (all p < 0.0001).
The last pre-transplant MELD score was, on average, 0.7
points higher in patients with NASH compared to
controls (Table 2).
Patients with NASH were slightly less frequently
transplanted from living donors (3.3 % vs. 5.1 %). The
use of immunosuppressive drugs was similar between
NASH and controls (p > 0.05) (Table 2).
De novo post-transplant type 2 diabetes
During post-transplant follow-up (average duration
3.0 ± 1.7 years), 39.8 % of NASH patients with at least
one follow-up record and without history of pre-
transplant DM vs. 27.0 % of controls had at least one
documented episode of de novo DM (p < 0.0001). Of
those, 65.9 % and 67.4 %, respectively, had their first
onset of DM recorded at the 6 months follow-up, and
79.0 % vs. 80.2 % had it by their 1 year follow-up.
Higher rate of de novo post-transplant DM in NASH
patients as compared to controls was observed starting
as early as 6 months post-transplant: 19.2 % vs. 13.9 %
(p < 0.0001). Later in follow-up, both cumulative and in-
cidental risks of developing post-transplant DM were
again consistently higher in NASH patients (Table 3,
Fig. 1). Indeed, 1 year after liver transplantation, the
relative risk (RR) of having had at least one episode of
de novo DM was RR (95%CI) = 1.37 (1.27–1.49); the
same risks by 3 and 5 years post-transplant were simi-
larly significant: 1.46 (1.35–1.57) and 1.47 (1.35–1.61),
respectively (all p < 0.0001). Furthermore, throughout
follow-up, NASH patients were found to be, on average,
1.47 times more likely to develop de novo DM post-
transplant in any given time period (hazard ratio
(HR) for time to development of DM: 1.47 (1.36–1.58),
p < 0.0001 (Fig. 1).
In multivariate analysis with a Cox proportional haz-
ard regression model (Table 4), after accounting for
potential risk factors such as higher rate of non-DM
metabolic syndrome components at pre-transplant,
being transplanted for NASH was still found to be
independently associated with an increased risk of
development of de novo post-transplant DM: aHR
(95 % CI) = 1.29 (1.18–1.42), p < 0.0001. Other pre-
dictors of de novo DM in post-liver transplant pa-
tients included older age (aHR = 1.017 (1.013–1.020)
per year), African-American race (aHR = 1.32 (1.16–1.51),
reference category: Caucasian), male gender (1.11 (1.03–
1.19)), being overweight (1.13 (1.04–1.24)) or obese (1.32
(1.21–1.45)) at transplant, and receiving steroids for
immunosuppression at transplant or later in follow-up
(but no later than the first onset of DM was recorded)
(1.87 (1.49–2.34)) (all p < 0.01). On the other hand, the
use of other immunosuppressive medications such as
tacrolimus and mycophenolates were not associated with
post-transplant DM (both p > 0.05) (Table 4).
Calendar year was associated with lower risk of devel-
oping de novo post-transplant DM: aHR = 0.923 (0.910–
0.935) per year. Indeed, of the study cohort transplanted
in 2004, 16.3 % developed DM at 6 months post-
transplant and 22.3 % by 1 year follow-up, while the
same rates for patients transplanted in 2011 were 10.1 %
and 12.2 %, respectively (both p < 0.0001) (Fig. 2).
Resolution of de novo post-transplant type 2 diabetes
Of patients who developed de novo post-transplant DM
and had at least two follow-up records, 74.5 % had reso-
lution of their DM later in follow-up. The rate of DM
resolution was similar between NASH patients and
controls (p > 0.05), and so was the time to resolution:
1.13 ± 1.06 years vs. 1.07 ± 0.99 years (p = 0.35). On
the other hand, the rate of long-term post-transplant
DM (DM that persisted for longer than 1 year and
thus was less likely to be immunosuppression-related)
was approximately 75 % higher in NASH patients:
7.6 % vs. 4.3 %, RR = 1.76 (1.49–2.08) (Table 3).
Table 1 Adult liver transplant recipients with NASH without
pre-transplant DM and controls
Parameter NASH w/o DM Controls w/o DM p
N 2916 14,268
Transplant years (N):
2003–2004 396 (13.6 %) 2371 (16.6 %)
2005–2006 536 (18.4 %) 2716 (19.0 %)
2007–2008 610 (20.9 %) 3058 (21.4 %)
2009–2010 690 (23.7 %) 3113 (21.8 %)
2011–2012 684 (23.5 %) 3010 (21.1 %) 0.05
Age, years 56.8 ± 10.4 50.8 ± 12.7 <0.0001
Race/ethnicity:
Caucasian 2378 (81.6 %) 10,384 (72.8 %) <0.0001
African-American 116 (4.0 %) 1289 (9.0 %) <0.0001
Asian 51 (1.7 %) 986 (6.9 %) <0.0001
Hispanic 352 (12.1 %) 1466 (10.3 %) 0.0041
Other race 19 (0.7 %) 143 (1.0 %) 0.07
Male gender 1637 (56.1 %) 8581 (60.1 %) 0.0001
U.S. citizen 2840 (97.4 %) 13,660 (95.7 %) <0.0001
College degree 657 (26.2 %) 3509 (29.1 %) 0.0031
Primary pay:
private insurance 1751 (60.3 %) 9308 (65.7 %) <0.0001
public insurance 1139 (39.2 %) 4737 (33.4 %) <0.0001
self-pay 12 (0.4 %) 126 (0.9 %) 0.0091
Employed 341 (13.3 %) 2119 (17.7 %) <0.0001
Functional status
(10–100 scale)
58.4 ± 23.9 58.4 ± 26.0 0.26
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Table 2 Pre-transplant clinical history and transplantation of liver transplant recipients with NASH without pre-transplant DM
NASH w/o DM Controls w/o DM p
BMI 30.1 ± 6.3 26.7 ± 5.6 <0.0001
Overweight (BMI 25–30) 871 (30.6 %) 4,608 (33.0 %) 0.0128
Obese (BMI > =30) 1,333 (46.9 %) 3,427 (24.6 %) <0.0001
Chronic obstructive pulmonary disease 29 (1.2 %) 164 (1.4 %) 0.47
Medically-treated hypertension 574 (23.4 %) 2,062 (17.2 %) <0.0001
Coronary artery disease 76 (3.1 %) 184 (1.5 %) <0.0001
Stroke 21 (0.8 %) 77 (0.6 %) 0.24
Peripheral vascular disease 24 (1.0 %) 108 (0.9 %) 0.73
Pulmonary embolism 8 (0.3 %) 45 (0.4 %) 0.72
Malignancy (solid organ or lymphoproliferative) 210 (7.2 %) 1,544 (10.9 %) <0.0001
Other solid organ transplants 7 (0.2 %) 106 (0.7 %) 0.0022
Primary liver malignancy 130 (4.5 %) 2,202 (15.4 %) <0.0001
TIPSS 300 (10.4 %) 1,073 (7.6 %) <0.0001
Transplantation
Last MELD score 22.8 ± 8.5 22.2 ± 9.9 <0.0001
Heterotopic transplant 3 (0.1 %) 15 (0.1 %) 0.97
Transplant from a living donor 97 (3.3 %) 729 (5.1 %) <0.0001
Donor’s age 43.2 ± 17.4 41.4 ± 17.6 <0.0001
Donor’s history of DM 315 (11.2 %) 1,357 (10.1 %) 0.06
Procurement from a non-heart beating donor 137 (4.9 %) 572 (4.2 %) 0.13
Number of HLA mismatches with a donor 4.52 ± 1.15 4.55 ± 1.14 0.39
Immunosuppressants used at transplant:
Mycophenolates 2,275 (78.2 %) 10,943 (76.9 %) 0.14
Tacrolimus 2,695 (92.6 %) 13,235 (93.0 %) 0.43
Steroids 2,763 (94.9 %) 13,519 (95.0 %) 0.88
Rejection episode before discharge 166 (6.2 %) 999 (7.8 %) 0.0031
Post-transplant inpatient stay, days 16.0 ± 18.7 15.6 ± 19.9 0.0498
Total inpatient stay, days 20.7 ± 36.2 20.1 ± 29.2 0.16
Non-compliant in follow-up (ever) 104 (4.0 %) 764 (6.0 %) 0.0001
Table 3 De novo type 2 diabetes at follow-up of liver transplant recipients with NASH
NASH w/o DM Controls w/o DM Relative risk (95 % CI) p
Incidence of de novo DM at:
6 months follow-up 499 (19.2 %) 1,737 (13.9 %) 1.38 (1.26–1.51) <0.0001
1 year follow-up 344 (14.3 %) 1144 (9.8 %) 1.46 (1.31–1.64) <0.0001
3 years follow-up 186 (11.4 %) 560 (6.8 %) 1.67 (1.43–1.96) <0.0001
5 years follow-up 73 (7.4 %) 275 (5.2 %) 1.43 (1.12–1.84) 0.0046
Had at least one onset of de novo post-transplant DM by:
1 year follow-up 624 (22.9 %) 2,196 (16.7 %) 1.37 (1.27–1.49) <0.0001
3 years follow-up 578 (32.7 %) 2,004 (22.4 %) 1.46 (1.35–1.57) <0.0001
5 years follow-up 425 (39.8 %) 1,548 (27.0 %) 1.47 (1.35–1.61) <0.0001
Recorded resolution of post-transplant DM after the first onset 621 (73.8 %) 2,205 (74.7 %) 0.99 (0.94–1.03) 0.59
Time from onset to resolution, years 1.13 ± 1.06 1.07 ± 0.99 0.35
Long-term de novo post-transplant DM 174 (7.6 %) 481 (4.3 %) 1.76 (1.49–2.08) <0.0001
Stepanova et al. BMC Gastroenterology  (2015) 15:175 Page 5 of 9
Discussion
Non-alcoholic fatty liver disease is considered to be hep-
atic manifestation of metabolic syndrome, a condition that
is growing rapidly worldwide synchronously with the epi-
demic of obesity. As a result, its progressive form of
NASH has already become the second most common in-
dication for liver transplantation in the United States after
hepatitis C infection and alcoholic liver disease [8, 9, 32].
Tightly connected with other metabolic syndrome
components, NAFLD and NASH pose substantial soci-
etal burden due to both associated risk of progression to
advanced stages and also their role in exacerbation of
other metabolic conditions such as insulin resistance
and type 2 diabetes. A number of potential pathophysio-
logic mechanisms that link NAFLD to IR/DM bi-
directionally based on the combination of insulin
desensitization with systemic and hepatic inflammation
have been suggested [4]. It is, however, unknown,
whether the increased risk of DM persists in NASH
patients after receiving a liver transplant. On the other
hand, current understanding of pathophysiology of both
NAFLD and insulin resistance suggests that, although
both conditions likely serve as direct risk factors for each
other, it is a systemic disorder that actually drives both
and, thus, is likely to remain in place even after success-
ful liver transplantation.
In this study of a national registry of solid organ
transplant recipients, we analyzed the rate of de novo
Fig. 1 Development of de novo post-transplant type 2 diabetes in liver transplant recipients with NASH vs. controls
Table 4 Predictors of development of de novo post-transplant
type 2 diabetes (adjusted hazard ratio with 95 % confidence
interval is calculated using Cox proportional hazard model).
Total N used in the model = 13,000: nc = 9999 censored,
ne = 3,001 events (de novo DM onset)
Predictor aHR (95 % CI) p
NASH 1.29 (1.18–1.41) <.0001
Calendar year 0.92 (0.91–0.94) <.0001
Age at transplant, per year 1.02 (1.01–1.02) <.0001
African-American 1.32 (1.16–1.51) <.0001
Hispanic 1.11 (0.99–1.24) 0.08
Asian 0.99 (0.84–1.17) 0.92
Male gender 1.11 (1.03–1.19) 0.0080
Overweight 1.13 (1.04–1.24) 0.0061
Obese 1.32 (1.21–1.45) <.0001
Liver malignancy 0.96 (0.86–1.08) 0.49
Pre-transplant CAD 1.19 (0.92–1.53) 0.19
Pre-transplant hypertension 1.05 (0.96–1.15) 0.27
Donor’s age, per year 1.002 (1.000–1.004) 0.0414
Procurement from a non-heart-beating donor 1.24 (1.04–1.46) 0.0140
Donor’s history of DM 1.09 (0.96–1.22) 0.18
Use of tacrolimus *) 0.98 (0.83–1.15) 0.80
Use of mycophenolates *) 0.92 (0.84–1.02) 0.11
Use of steroids *) 1.87 (1.49–2.34) <.0001
*) Ever used before the first onset of post-transplant DM
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post-transplant DM in patients transplanted for
NASH who did not have a recorded history of type 2
diabetes before transplantation, and compared that to
controls with non-HCV-related chronic liver disease,
since other indications for liver transplantation are
not expected to be driven by any systemic IR-related
abnormalities. Due to limitations of the SRTR data
collection used in this study, only patients with up to
5 years of follow-up transplanted after 2003 were
included. Pediatric patients were also not included in
this study, although the rapidly growing rate of child-
hood obesity and associated NAFLD suggests that this
cohort may become an important contributor to the
overall burden of NASH-associated end-stage liver
disease in the nearest future [33].
Our results confirm the increased risk of developing
post-transplant type 2 diabetes in patients trans-
planted for NASH. Although the incidence of DM
was found to be decreasing over time regardless of
liver disease etiology, both incidental and cumulative
risks of de novo post-transplant DM remained con-
sistently higher in the NASH cohort throughout the
duration of follow-up. In fact, patients transplanted
for NASH had, on average, 35–60 % higher risk of
developing de novo post-transplant DM at any mo-
ment after transplantation. Furthermore, NASH pa-
tients had an approximately 65 % higher risk of
developing DM that would last for more than 1 year,
indicating that even after accounting for intense im-
munosuppression shortly after transplantation, which
is known to be a major contributor to developing
post-transplant DM by itself, NASH patients still re-
main at higher risk of DM.
Although patients transplanted for NASH also had
other medical conditions that could potentially be
responsible for an increased risk of having DM, such as
obesity, even after adjustment for the baseline con-
founders, the association of pre-transplant NASH and
de novo post-transplant DM remained significant. On
the other hand, other predictors of de novo post-
transplant DM reported in this study are consistent with
previous reports and include older age, male gender,
African-American race and being overweight or obese
before transplantation. Another important predictor of
lower risk of post-transplant DM was calendar year,
suggesting that post-transplant management of liver
transplant recipients is rapidly improving.
Our results have important clinical implications. In
particular, in addition to all health risks associated with
DM itself, having DM post-transplant was found to be
associated with an increased risk of post-transplant
mortality after accounting for a number of potential
confounders [34, 35]. Furthermore, given the high rate
of NASH recurrence in transplanted patients and that
NASH may be both driven by and at the same time in-
crease the risk of post-transplant DM, with longer
follow-up, a higher risk of graft loss and the need to re-
transplant is also possible. Therefore, post-transplant
management of NASH patients, including the choice of
immunosuppressants, should account for those in-
creased risks in order to reduce the rate of unfavorable
outcomes.
To the limitations of this study, we could not fully as-
sess the effect of post-transplant immunosuppressive
medications on development and resolution of post-
transplant DM because they were reported without
Fig. 2 One year post-transplant prevalence of de novo type 2 diabetes in NASH patients and in controls by year. p < 0.05 for all years except
for 2011
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dosage or other details of the regimen, thus, limiting our
ability to accurately account for their diabetogenic effect.
We also had to rely on candidates’ medical records to
rule in and rule out the presence of type 2 DM before
transplantation, rather than use universal diagnostic
criteria, which may be not absolutely accurate due to
variability in coding practices across transplant centers.
Conclusion
In conclusion, in this study of the nationwide registry of
patients receiving liver transplantation, we have con-
firmed that, in addition to previously known risk factors,
patients transplanted for NASH are at a greater risk of
developing de novo post-transplant DM even in the ab-
sence of type 2 diabetes before transplantation. This sug-
gests the presence of an underlying metabolic disorder
beyond fatty liver that may be causative for developing
of both NASH and DM, and should guide clinicians for
long-term management of patients undergoing liver
transplantation for NASH.
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